Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EZH2 Inhibition: A Promising Strategy to Prevent Cancer Immune Editing
Ning Kang, Mark Eccleston, Pier‐Luc Clermont, et al.
Epigenomics (2020) Vol. 12, Iss. 16, pp. 1457-1476
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

The long and short non-coding RNAs modulating EZH2 signaling in cancer
Sepideh Mirzaei, Mohammad Gholami, Kiavash Hushmandi, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 138
Tazemetostat: EZH2 Inhibitor
Rachael Straining, William Eighmy
Journal of the Advanced Practitioner in Oncology (2022) Vol. 13, Iss. 2, pp. 158-163
Open Access | Times Cited: 99
EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy
Shanshan Sun, Yu Feng, Danying Xu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 2, pp. 188700-188700
Open Access | Times Cited: 49
Impact of epigenetic reprogramming on antitumor immune responses in glioma
Brandon L. McClellan, Santiago Haase, Felipe J. Núñez, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 2
Open Access | Times Cited: 38
Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities
Feng‐Ming Tien, Hsuan‐Hsuan Lu, Shu‐Yung Lin, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 20
Epigenetics-Based Diagnostic and Therapeutic Strategies: Shifting the Paradigm in Prostate Cancer
Pier‐Luc Clermont
Epigenomics (2023) Vol. 15, Iss. 2, pp. 75-87
Closed Access | Times Cited: 19
Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition
Shengwei Tao, Shuhang Liang, Taofei Zeng, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 17
The molecular mechanisms and therapeutic potential of EZH2 in breast cancer
Sara Adibfar, Marischa Elveny, Hadisha Sh. Kashikova, et al.
Life Sciences (2021) Vol. 286, pp. 120047-120047
Closed Access | Times Cited: 33
EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies
Ivana Samaržija, Marko Tomljanović, Renata Novak Kujundžić, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4761-4761
Open Access | Times Cited: 23
Epigenetic Signaling and Crosstalk in Regulation of Gene Expression and Disease Progression
Soumen K. Manna, Jagdish Mishra, Tirthankar Baral, et al.
Epigenomics (2023) Vol. 15, Iss. 14, pp. 723-740
Closed Access | Times Cited: 16
EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines
Maryam Latarani, Perla Pucci, Mark Eccleston, et al.
Epigenomics (2025), pp. 1-10
Open Access
Ezh2 Shapes T Cell Plasticity to Drive Atherosclerosis
Cecilia Assunta Bonfiglio, Michael Lacy, Vasiliki Triantafyllidou, et al.
Circulation (2025)
Closed Access
Computational exploration in search for novel natural product-derived EZH2 inhibitors for advancing anti-cancer therapy
Sagar Singh Shyamal
Molecular Diversity (2025)
Closed Access
The Landscape of Histone Modifications in Epigenomics Since 2020
Milad Shirvaliloo
Epigenomics (2022) Vol. 14, Iss. 23, pp. 1465-1477
Closed Access | Times Cited: 17
Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
Nithya Krishnamurthy, Shumei Kato, Scott M. Lippman, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 9, pp. e004669-e004669
Open Access | Times Cited: 16
Simultaneous Delivery of Doxorubicin and EZH2‐Targeting siRNA by Vortex Magnetic Nanorods Synergistically Improved Anti‐Tumor Efficacy in Triple‐Negative Breast Cancer
Yunshu Lu, Fenfen Gu, Yuwei Ma, et al.
Small (2023) Vol. 19, Iss. 43
Open Access | Times Cited: 9
EZH2-Myc Hallmark in Oncovirus/Cytomegalovirus Infections and Cytomegalovirus’ Resemblance to Oncoviruses
Ranim El Baba, Georges Herbein
Cells (2024) Vol. 13, Iss. 6, pp. 541-541
Open Access | Times Cited: 3
Targeting epigenetic mechanisms of resistance to chemotherapy in gliomas
Panagiotis Skouras, Mariam Markouli, Ioanna Papadatou, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104532-104532
Closed Access | Times Cited: 3
PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer
Juyeong Hong, Ji Hoon Lee, Zhao Zhang, et al.
Cancer Research (2022) Vol. 82, Iss. 24, pp. 4624-4640
Open Access | Times Cited: 13
Epigenetic therapeutic strategies in pancreatic cancer
Arturo Orlacchio, Stephen Muzyka, Tamas A. Gonda
International review of cell and molecular biology (2024), pp. 1-40
Closed Access | Times Cited: 2
Inhibition of EZH2 Ameliorates Sepsis Acute Lung Injury (SALI) and Non-Small-Cell Lung Cancer (NSCLC) Proliferation through the PD-L1 Pathway
Ziyi Wang, Zhe Guo, Xuesong Wang, et al.
Cells (2022) Vol. 11, Iss. 24, pp. 3958-3958
Open Access | Times Cited: 11
It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective
Anniek Zaalberg, Elisabeth Pottendorfer, Wilbert Zwart, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 294-294
Open Access | Times Cited: 2
The Road Ahead in Pancreatic Cancer: Emerging Trends and Therapeutic Prospects
T. P. Chris, Jack Y. Prochnau, A. Mediero Domínguez, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 1979-1979
Open Access | Times Cited: 2
Long noncoding RNA DLGAP1-AS1 promotes the progression of glioma by regulating the miR-1297/EZH2 axis
Liang Liu, Xiaojian Li, Yan Shi, et al.
Aging (2021) Vol. 13, Iss. 8, pp. 12129-12142
Open Access | Times Cited: 14
EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells
Laura Damele, Adriana Amaro, Alberto Serio, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 319-319
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top